A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Inclusion Criteria: * Diagnosis of allergic rhinitis * In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs * Males or females who are surgically sterilized, post menopausal for the past year, or are using two acceptable methods of contraception against pregnancy through at least 6 months after the dose of study drug Exclusion Criteria: * History or clinical manifestations of significant metabolic, hepatic, renal, hematologic, immunodeficiency, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders * History of anaphylaxis, hypersensitivity or drug allergies * Use of a non-biologic investigational drug or participation in an investigational study with a non-biologic drug within 30 days prior to dosing * Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 3 months prior to dosing * Positive blood test for chronic viral infections by: hepatitis B surface antigen, hepatitis C virus antibody, or HIV antibody